Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Expenses (2020 - 2025)

Apellis Pharmaceuticals has reported Operating Expenses over the past 6 years, most recently at $251.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $251.1 million for Q4 2025, up 5.18% from a year ago — trailing twelve months through Dec 2025 was $948.4 million (changed 0.21% YoY), and the annual figure for FY2025 was $948.4 million, changed 0.21%.
  • Operating Expenses for Q4 2025 was $251.1 million at Apellis Pharmaceuticals, up from $235.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for APLS hit a ceiling of $251.1 million in Q4 2025 and a floor of $124.6 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $217.7 million (2023), compared with a mean of $204.1 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 68.74% in 2021 and later decreased 15.37% in 2022.
  • Apellis Pharmaceuticals' Operating Expenses stood at $149.7 million in 2021, then rose by 24.73% to $186.7 million in 2022, then increased by 23.66% to $230.9 million in 2023, then increased by 3.38% to $238.7 million in 2024, then grew by 5.18% to $251.1 million in 2025.
  • The last three reported values for Operating Expenses were $251.1 million (Q4 2025), $235.4 million (Q3 2025), and $211.8 million (Q2 2025) per Business Quant data.